These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 12775533)

  • 21. Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.
    Mela Osorio MJ; Ferrari L; Goette NP; Gutierrez MI; Glembotsky AC; Maldonado AC; Lev PR; Alvarez C; Korin L; Marta RF; Molinas FC; Heller PG
    Eur J Haematol; 2016 Apr; 96(4):435-42. PubMed ID: 26119186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Diagnostic and therapeutic management of essential thrombocythemia in children].
    Mitura-Lesiuk M; Filiks-Litwin B; Małek U; Kowalczyk JR
    Med Wieku Rozwoj; 2004; 8(3 Pt 2):834-8. PubMed ID: 15858255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.
    Ito T; Hashimoto Y; Tanaka Y; Nakaya A; Fujita S; Satake A; Nakanishi T; Konishi A; Hotta M; Yoshimura H; Ishii K; Hashimoto A; Kondo T; Omura H; Shinzato I; Tanaka T; Nomura S
    Eur J Haematol; 2019 Aug; 103(2):116-123. PubMed ID: 31107982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial].
    Ge X; Yang L; Jin J; Qian W; Li J; Yang R; Cao X; Jiang B; Wang Z; Hou M; Zhang W; Xiao Z; Zhao Y; Gao D; Zhang X; Wang S; Sun A; Fu J; Su L; Li K
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):547-52. PubMed ID: 26304075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia.
    Gugliotta L; Tieghi A; Tortorella G; Scalzulli PR; Ciancia R; Lunghi M; Cacciola E; Cacciola R; Candoni A; Crugnola M; Codeluppi K; Usala E; Specchia G; Martinelli V; Palmieri F; Pierri I; Liberati AM; Iurlo A; Grossi A; Vannucchi AM; Vianelli N; Mazzucconi MG
    Leuk Res; 2011 Dec; 35(12):1557-63. PubMed ID: 21764130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide.
    Griesshammer M
    Expert Rev Hematol; 2009 Jun; 2(3):227-36. PubMed ID: 21082965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Anagrelide for treatment of patients with essential thrombocythaemia].
    Boban A; Sertić D; Radman I; Zupancić-Salek S; Zadro R; Labar B
    Lijec Vjesn; 2008; 130(5-6):141-5. PubMed ID: 18792562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of anagrelide in childhood essential thrombocythemia.
    Kanai A; Morokawa H; Matsuda K; Shimazaki E; Nakazawa Y
    Pediatr Int; 2017 Sep; 59(9):1017-1018. PubMed ID: 28707720
    [No Abstract]   [Full Text] [Related]  

  • 29. Anagrelide, a selective thrombocytopenic agent.
    Oertel MD
    Am J Health Syst Pharm; 1998 Oct; 55(19):1979-86. PubMed ID: 9784784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia.
    Kanakura Y; Shirasugi Y; Yamaguchi H; Koike M; Chou T; Okamoto S; Achenbach H; Wu J; Nakaseko C
    Int J Hematol; 2018 Nov; 108(5):491-498. PubMed ID: 30121892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide.
    Cacciola RR; Cipolla A; Di Francesco E; Giustolisi R; Cacciola E
    Am J Hematol; 2005 Sep; 80(1):81-3. PubMed ID: 16138352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Primary thrombocythemia: diagnosis and therapy].
    Petrides PE
    Med Klin (Munich); 2006 Aug; 101(8):624-34. PubMed ID: 16896569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Essential thrombocythemia: diagnosis and treatment, with special emphasis on the use of anagrelide.
    Andersson BS
    Hematology; 2002 Jun; 7(3):173-7. PubMed ID: 12243981
    [No Abstract]   [Full Text] [Related]  

  • 34. Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study.
    Besses C; Kiladjian JJ; Griesshammer M; Gugliotta L; Harrison C; Coll R; Smith J; Abhyankar B; Birgegård G
    Leuk Res; 2013 Feb; 37(2):162-8. PubMed ID: 23199894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.
    Balduini CL; Bertolino G; Noris P; Ascari E
    Haematologica; 1992; 77(1):40-3. PubMed ID: 1398280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia.
    Laguna MS; Kornblihtt LI; Marta RF; Michiels JJ; Molinas FC
    Clin Appl Thromb Hemost; 2000 Jul; 6(3):157-61. PubMed ID: 10898276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.
    Birgegård G
    Curr Hematol Malig Rep; 2016 Oct; 11(5):348-55. PubMed ID: 27497846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
    Prescrire Int; 2006 Jun; 15(83):83-6. PubMed ID: 16764090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inverted takotsubo cardiomyopathy in a patient with essential thrombocythemia exposed to anagrelide and phentermine.
    Dziewierz A; Olszanecka A; Wiliński J; Rakowski T; Kleczyński P; Dubiel JS; Dudek D
    Int J Cardiol; 2012 Oct; 160(2):e31-2. PubMed ID: 22406466
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-term use of anagrelide in the treatment of children with essential thrombocythemia.
    Lackner H; Urban C; Benesch M; Moser A; Sovinz P; Schwinger W; Dornbusch HJ
    Eur J Haematol; 2006 Oct; 77(4):358-9. PubMed ID: 16856926
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.